Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 28 September 1984:
Vol. 225. no. 4669, pp. 1487 - 1489
DOI: 10.1126/science.6332379
Prev | Table of Contents | Next

Articles

Science, Vol 225, Issue 4669, 1487-1489
Copyright © 1984 by American Association for the Advancement of Science

articles

Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2

JJ Mule, S Shu, SL Schwarz, and SA Rosenberg

The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) of these tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity.
A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al. (2008)
J Natl Cancer Inst 100, 950-961
   Abstract »    Full Text »    PDF »
Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors.
H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern (2006)
J. Immunol. 177, 4288-4298
   Abstract »    Full Text »    PDF »
Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo.
P. A. Antony, C. M. Paulos, M. Ahmadzadeh, A. Akpinarli, D. C. Palmer, N. Sato, A. Kaiser, C. Heinrichs, C. A. Klebanoff, Y. Tagaya, et al. (2006)
J. Immunol. 176, 5255-5266
   Abstract »    Full Text »    PDF »
Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors.
K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello (2005)
Cancer Res. 65, 2026-2034
   Abstract »    Full Text »    PDF »
Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene.
T. Murakami, N. Tokunaga, T. Waku, S. Gomi, S. Kagawa, N. Tanaka, and T. Fujiwara (2004)
Clin. Cancer Res. 10, 3871-3880
   Abstract »    Full Text »    PDF »
In Vivo Antitumor Activity of Interleukin 21 Mediated by Natural Killer Cells.
G. Wang, M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J. Leonard, and P. Hwu (2003)
Cancer Res. 63, 9016-9022
   Abstract »    Full Text »    PDF »
Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein.
K. Shimizu, E. K. Thomas, M. Giedlin, and J. J. Mulé (2001)
Cancer Res. 61, 2618-2624
   Abstract »    Full Text »
Prostaglandin E2 Suppressed IL-15-Mediated Human NK Cell Function Through Down-Regulation of Common {{gamma}}-Chain.
P. C. Joshi, X. Zhou, M. Cuchens, and Q. Jones (2001)
J. Immunol. 166, 885-891
   Abstract »    Full Text »    PDF »
Antitumor Cytotoxicity Mediated by Ligand-activated Human V{{alpha}}24 NKT Cells.
T. Kawano, T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. (1999)
Cancer Res. 59, 5102-5105
   Abstract »    Full Text »    PDF »
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule (1999)
PNAS 96, 2268-2273
   Abstract »    Full Text »    PDF »
Role of Spontaneous and Interleukin-2-Induced Natural Killer Cell Activity in the Cytotoxicity and Rejection of Fas+ and Fas- Tumor Cells.
M. Bradley, A. Zeytun, A. Rafi-Janajreh, P. S. Nagarkatti, and M. Nagarkatti (1998)
Blood 92, 4248-4255
   Abstract »    Full Text »    PDF »
Treatment of B-Cell Lymphoma With Chimeric IgG and Single-Chain Fv Antibody-Interleukin-2 Fusion Proteins.
S.-J. Liu, Y.-P. Sher, C.-C. Ting, K.-W. Liao, C.-P. Yu, and M.-H. Tao (1998)
Blood 92, 2103-2112
   Abstract »    Full Text »    PDF »
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
R. C. Fields, K. Shimizu, and J. J. Mule (1998)
PNAS 95, 9482-9487
   Abstract »    Full Text »    PDF »
Natural killer cell lines kill autologous beta 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy.
A. Porgador, O. Mandelboim, N. P. Restifo, and J. L. Strominger (1997)
PNAS 94, 13140-13145
   Abstract »    Full Text »    PDF »
Inhibition of Lymphocyte Function by Head and Neck Carcinoma Cell Line Soluble Factors.
J. W. Bailet, A. Lichtenstein, G. Chen, and R. A. Mickel (1997)
Arch Otolaryngol Head Neck Surg 123, 855-862
   Abstract »    PDF »
Sensitization of Nude Mice Using Direct Liposome Transfer of Tumor Cell Antigens.
T. Ariyasu, O. Ike, S. Hitomi, H. Wada, Y. Okumura, and J. Sunamoto (1996)
Journal of Bioactive and Compatible Polymers 11, 191-202
   Abstract »
Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid.
D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu (1995)
Reproductive Sciences 2, 762-771
   Abstract »    PDF »
Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2.
S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White (1994)
JAMA 271, 907-913
   Abstract »    PDF »
Adoptive Cellular Therapy of Malignancy.
A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu (1993)
Arch Surg 128, 1281-1290
   Abstract »    PDF »
Treatment of Human Melanoma Hepatic Metastases in Nude Mice With Human Cytotoxic T Lymphocytes.
N. J. Crowley, C. E. Vervaert, and H. F. Seigler (1991)
Arch Surg 126, 433-437
   Abstract »    PDF »
Depressed Lymphokine Activated Killer Cell Activity in Mycosis Fungoides: A Possible Marker for Aggressive Disease.
N. L. Wood, E. N. Kitces, and W. K. Blaylock (1990)
Arch Dermatol 126, 907-913
   Abstract »    PDF »
A New Regimen of Interleukin 2 and Lymphokine-Activated Killer Cells: Efficacy Without Significant Toxicity.
T. J. Eberlein, D. D. Schoof, S.-E. Jung, D. Davidson, B. Gramolini, K. McGrath, A. Massaro, and R. E. Wilson (1988)
Arch Intern Med 148, 2571-2576
   Abstract »    PDF »
Biomaterials and biomedical devices.
J. Hanker and B. Giammara (1988)
Science 242, 885-892
   Abstract »    PDF »
New Approaches to the Immunotherapy of Cancer Using Interleukin-2.
S. A. ROSENBERG, M. T. LOTZE, and J. J. MULE (1988)
Ann Intern Med 108, 853-864
   Abstract »    PDF »
Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial.
R. I. FISHER, C. A. COLTMAN Jr., J. H. DOROSHOW, A. A. RAYNER, M. J. HAWKINS, J. W. MIER, P. WIERNIK, J. D. MCMANNIS, G. R. WEISS, K. A. MARGOLIN, et al. (1988)
Ann Intern Med 108, 518-523
   Abstract »    PDF »
Dermatologic Changes Associated With Interleukin 2 Administration.
A. A. Gaspari, M. T. Lotze, S. A. Rosenberg, J. B. Stern, and S. I. Katz (1987)
JAMA 258, 1624-1629
   Abstract »    PDF »
Immunomodulators in Clinical Medicine.
A. S. FAUCI, S. A. ROSENBERG, S. A. SHERWIN, C. A. DINARELLO, D. L. LONGO, and H. C. LANE (1987)
Ann Intern Med 106, 421-433
   Abstract »    PDF »
High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings.
M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto, and S. A. Rosenberg (1986)
JAMA 256, 3117-3124
   Abstract »    PDF »
Intraperitoneal Administration of Interleukin-2 in Patients With Cancer.
M. T. Lotze, M. C. Custer, and S. A. Rosenberg (1986)
Arch Surg 121, 1373-1379
   Abstract »    PDF »
Continuous Intrasplenic Interleukin-2 Combined With Antigen-Specific Chemoimmunotherapy.
K. Naito, N. R. Pellis, and B. D. Kahan (1986)
Arch Surg 121, 1415-1420
   Abstract »    PDF »
Suppression of Cellular Immunity by Head and Neck Irradiation: Precipitating Factors and Reparative Mechanisms in an Experimental Model.
W. C. Gray, B. J. Hasslinger, C. M. Suter, C. L. Blanchard, A. L. Goldstein, and P. B. Chretien (1986)
Arch Otolaryngol Head Neck Surg 112, 1185-1190
   Abstract »    PDF »
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
S. Rosenberg, P Spiess, and R Lafreniere (1986)
Science 233, 1318-1321
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)